Sigmoid Pharma to Present Corporate Overview at the 36th Annual Cowen & Company Healthcare Conference
Dublin (Ireland), March 1, 2016 SIGMOID PHARMA LIMITED, a privately-owned, specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases as well as immuno-oncology related complications using its proprietary SmPill solid oral delivery system, announced today that Dr. Ivan Coulter, Chief Executive Officer, will provide a corporate update at the 36th Annual Cowen & Co. Healthcare Conference, taking place in Boston, Massachusetts March 7-9, 2016.
Presentation Details:
Title: 36th Annual Cowen & Company Healthcare Conference
Date: March 9th
Time: 10:30am Eastern Time
Location: MIT Room, The Marriott Copley Hotel, Boston.
About Sigmoid Pharma
Sigmoid Pharma is a clinical-stage specialty pharmaceutical company dedicated to the development of novel, targeted drugs in the therapeutic areas of gastrointestinal and immunological diseases as well as immuno-oncology related complications. The Companys Single-Multiple Pill (SmPill) technology is a versatile delivery system for optimising the formulation of active therapeutic agents and allowing targeted release at the site of disease. Sigmoids lead program is CyCol, a colon-targeted, formulation of cyclosporine that permits local, topical exposure of a powerful immunosuppressant whilst minimizing systemic blood levels, thus offering the potential for an efficacious and safe oral treatment of moderate-severe ulcerative colitis (UC). Another pipeline product is has received US FDA Orphan Designation for Graft-versus-Host Disease. For additional information please visit: http://www.sigmoidpharma.com
For further information contact:
Leo Toole
Chief Financial Officer
Sigmoid Pharma Ltd,
Blocks 9/10 Nexus UCD, Belfield Office Park,
Beech Hill Road, Dublin 4, D04 V2N9, Ireland.
Phone +353 (0) 1 700 7452
E-mail: info@sigmoidpharma.com
US Investors:
Andrew McDonald Ph.D.
LifeSci Advisors LLC
andrew@lifesciadvisors.com